The promise of precision cancer therapy meets a concerning reality: treatments designed to destroy tumors may inadvertently strengthen their immunological defenses. This finding challenges assumptions about how chemotherapy and targeted drugs reshape the cellular battlefield within tumors, potentially explaining why some cancers become harder to eliminate over time.
Researchers analyzing lung adenocarcinoma tissue discovered that TREM2-expressing macrophages become more abundant in tumors compared to healthy lung tissue. Using single-cell RNA sequencing on human samples and mouse models, they found cisplatin chemotherapy specifically increases the proportion of TREM2-positive M2 macrophages within tumors. The targeted therapy osimertinib similarly elevated TREM2 expression in laboratory-cultured macrophages. These TREM2-expressing cells communicate with other immune cell populations through FN:CD44 and MIF:CD74 signaling pathways, orchestrating recruitment of additional immunosuppressive cells to the tumor environment.
This discovery illuminates a troubling treatment paradox in oncology. TREM2-positive macrophages create immunosuppressive conditions that help tumors evade immune surveillance and resist therapy. The fact that standard treatments amplify this population suggests current protocols may inadvertently undermine their own effectiveness. While cisplatin enhanced macrophage uptake of cellular debris—potentially beneficial for clearing dead tumor cells—the simultaneous increase in immunosuppressive activity represents a significant therapeutic liability. These findings demand reconsideration of combination strategies that could neutralize TREM2-mediated immunosuppression while preserving chemotherapy's tumor-killing effects. The research remains preliminary, conducted primarily in cell culture and mouse models, requiring validation in larger human cohort studies before influencing clinical practice.